Tetrahydroisoquinolinylmethylbenzamide MOR Agonists With Fewer Side Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing heterocyclic compounds used as MOR agonists for treating opioid receptor-associated conditions, such as pain and gastrointestinal issues, often cause adverse effects like respiratory depression, tolerance, dependence, and addiction, necessitating the development of new MOR modulators with fewer side effects.
Innovation Solution
Development of tetrahydroisoquinolinylmethylbenzamide compounds as potent MOR agonists, characterized by specific structural features and variations in R groups, which activate MOR with reduced side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional heterocyclic compounds are used as MOR agonists, then analgesic effect is achieved, but adverse effects such as respiratory depression, tolerance, dependence, and addiction occur
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of MOR agonists through systematic variation of R1-R6 substituents and molecular frameworks. This structural parameter optimization enables the compounds to maintain potent analgesic activity while reducing activation of off-target receptors that cause adverse effects like respiratory depression and dependence
Solution Approach 2:
The invention employs composite molecular structures combining tetrahydroisoquinoline core with various aromatic and heterocyclic substituents. These composite structures achieve selective MOR agonism by optimizing the balance between hydrophobic interactions, hydrogen bonding, and steric fit within the receptor binding pocket, thereby improving therapeutic index
2Duration of action of stationary object
If long-term use of MOR agonists is implemented for chronic pain control, then pain management is maintained, but severe side effects such as tolerance, dependence, and addiction develop
Solution Approach 1:
The patent applies local quality by introducing specific substituent patterns at defined positions (R1-R6) that locally modify receptor interaction characteristics. Certain substituents enhance analgesic potency while others reduce affinity for receptors involved in tolerance and dependence pathways, enabling differentiated local effects within the same molecular framework
Solution Approach 2:
The invention segments the MOR agonist molecule into distinct functional domains: the core tetrahydroisoquinoline structure provides baseline activity, while variable R1-R6 substituents independently modulate specific pharmacological properties. This segmentation allows rational design of compounds with optimized chronic use profiles by selecting appropriate substituent combinations
Data Source
AI summary
Disclosed are tetrahydroisoquinoline compounds useful for treating an opioid receptor-associated condition including pain, immune disease, esophageal reflux, diarrhea, anxiety, or heroin addiction. Also provided are pharmaceutical compositions and treatment methods.